Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study-Reference-Cited by-同舟云学术

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study

Published:2016-08 Issue: Volume:98 Page:9-14
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Cadranel Jacques,Park Keunchil,Arrieta Oscar,Pless Miklos,Bendaly Edmond,Patel Dony,Sasane Medha,Nosal Adam,Swallow Elyse,Galebach Philip,Kageleiry Andrew,Stein Karen,Degun Ravi,Zhang Jie

Funder

Novartis Pharmaceuticals Corporation to Analysis Group, Inc. Analysis Group

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Cancer Facts & Figures;American Cancer Society,2015

2. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas;Boland;Hum. Pathol.,2009

3. ALK inhibitors in the treatment of advanced NSCLC;Gridelli;Cancer Treat. Rev.,2014

4. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers;Inamura;J. Thorac. Oncol.,2008

5. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin. Cancer Res.,2008

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Les patients ALK et ROS1 : quelle séquence ?;Revue des Maladies Respiratoires Actualités;2022-10

2. Les patients ALK et ROS1 : quelle séquence ?;Revue des Maladies Respiratoires Actualités;2021-09

3. Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib;Future Oncology;2021-06

4. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2021-01

5. Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP);Future Oncology;2021-01